Jim Cramer Is Bullish On Cannabis Stocks Ahead Of Midterm Elections: ‘I Say Buy Tilray’
Mad Money host Jim Cramer said last week during a Lightning Round segment that now is a good time to invest in Tilray.
Acreage Holdings Q3 Financial Results, A “Highly Attractive Positioning”
Acreage Holdings, Inc.(CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), reported its financial results late Monday for the third quarter ended September 30, 2022 (“Q3 2022”).
What Happens To Cannabis Bills If Republicans Take House And Senate? Here’s One View
"The Risk of a Post-Election Funk”
Forget About SAFE Plus Or CLIMB Act As Cannabis Stock Catalysts, With Canopy’s Potential Exception
Canopy Growth Corporation (NASDAQ: CGC)
Cantor Fitzgerald Maintains Neutral on Canopy Gwth, Raises Price Target to $3.3
Cantor Fitzgerald analyst Pablo Zuanic maintains Canopy Gwth (NASDAQ:CGC) with a Neutral and raises the price target from $3.05 to $3.3.
“Biden Promotes His Marijuana Pardons Days Before The Election, But Reiterates Relief Is ‘Just For Possession'” – Marijuana Moment
Biden Promotes His Marijuana Pardons Days Before The Election, But Reiterates Relief Is 'Just For Possession' - Marijuana Moment
President Joe Biden is again touting his mass marijuana pardons ahead of the
‘Maryland Marijuana Legalization Campaign Targets Young Voters In New Ad To Boost Election Turnout’ -Marijuana Moment Report
https://www.marijuanamoment.net/maryland-marijuana-legalization-campaign-targets-young-voters-in-new-ad-to-boost-election-turnout/
Cannabis Stock Gainers And Losers From November 2, 2022
GAINERS:
LOSERS:
RIV Capital (OTC:CNPOF) shares closed down 12.25% at $0.30
‘New Jersey Governor Says State Should ‘Revisit’ Marijuana Home Grow Ban After Market Matures’
https://www.marijuanamoment.net/new-jersey-governor-says-state-should-revisit-marijuana-home-grow-ban-after-market-matures/
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.